Global Cervical Dysplasia Market Is Anticipated To Witness Growth Due To Growing Incidences Of Cervical Cancer And Rising Awareness Regarding Cancer Diagnosis
Cervical Dysplasia |
Overview:
Cervical Dysplasia is a condition
where abnormal cells form on the cervix, which is the lower portion of the
uterus. It occurs most often in women who are childbearing age and are infected
with the human papillomavirus (HPV). Although cervical dysplasia is not cancer,
it can develop into cervical cancer if it is not diagnosed and treated early. There
are two types of cervical dysplasia. First is mild, which is characterized by a
few abnormal cells. This type of dysplasia will clear up on its own. However, a
mild form of dysplasia may require periodic Pap smears to check for changes. Another
form of dysplasia is moderate, which is characterized by a larger number of
abnormal cells. Treatment for moderate dysplasia involves cryotherapy, surgical
removal, or ablation of the affected area. High-grade squamous intraepithelial
lesion is a severe form of dysplasia. This is the most common type of cervical
dysplasia.
Market Dynamics:
Growing product approvals is estimated to
augment growth of the Global
Cervical Dysplasia Market during the forecast period. For
instance, HPV DNA Diagnostic Kit by SANSURE BIOTECH INC., was approved by the
China National Medical Products Administration in January 2022. This kit has
been developed with 13 types of high-risk genotypes and advanced magnetic beads
technology, it is capable of screening cervical cancer. Moreover, increasing
costs of devices is anticipated to restrain growth of the global cervical
dysplasia market during the forecast period.
Impact of COVID-19:
The outbreak of COVID-19 was first
witnessed in December 2019, in Wuhan. Later on, this disease spread to more
than a 100 nations. It was declared as a
public health emergency by the World Health Organization in 2020. This led to shutting down of many businesses
and affected the economy of many nations. COVID-19 affected the healthcare
sector in a severe manner, as the number of people suffering from the disease
were increasing daily in all countries. Lockdowns were imposed to prevent the
transmission of the virus. Hospitals were almost full and COVID-19 patients
were prioritized for treatment. This hampered the growth of the Global Cervical Dysplasia Market, as
these treatments were either delayed or postponed.
Key Takeaways:
The Global Cervical Dysplasia Market is
estimated to witness robust growth, exhibiting CAGR of XX% during the forecast
period, owing to increasing expansion by key players. For instance, Sierra
Oncology and GlaxoSmithKline Plc., declared their strategic partnership in
April 2022. Under this partnership, Sierra will be acquired by GSK for US$ 55
per share of common stock in cash.
North America is anticipated to witness
significant growth in the global cervical dysplasia market over the forecast
period, due to growing incidences of cervical cancer.
Key Players Active
In The Global Cervical Dysplasia Market Are Abbott Laboratories, Becton,
Dickinson, and Company, Asieris Pharmaceuticals, Bristol-Myers Squibb Company,
ASKA Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, KinoPharma, Inc., Micromedic
Technologies Ltd., CooperSurgical, Inc., Karl Kaps GmbH & Co. KG,
BetterLife Pharma, Inc., Hologic, Inc., PDS Biotechnology Company, and Polaris
Pharmaceuticals, Inc.
Comments
Post a Comment